Phase 2 Japanese Registration Trial of Ziftomenib (KOMZIFTI) in Relapsed or Refractory NPM1‑Mutated Acute Myeloid Leukemia

Kyowa Kirin Co., Ltd. has announced the initiation of a single‑arm, open‑label Phase 2 registration trial (jRCT2031250550) to evaluate the safety and efficacy of ziftomenib, an oral menin inhibitor, in patients with relapsed or refractory NPM1‑mutated acute myeloid leukemia (AML). The study targets a population that accounts for a substantial proportion of AML cases, thereby addressing a significant unmet therapeutic need.

Study Design and Objectives

  • Population: Adults with relapsed or refractory NPM1‑mutated AML, a subgroup for which few effective options remain after standard therapy failure.
  • Intervention: Oral ziftomenib administered at the established dosing schedule derived from earlier phase trials.
  • Primary Endpoint: Composite complete remission (CR) rate, defined as the proportion of patients achieving either a complete remission (CR) or a complete remission with partial hematologic recovery (CRh).
  • Secondary Endpoints: Duration of response, overall survival, minimal residual disease negativity rates, safety profile, and pharmacokinetic parameters.

The trial will provide pivotal data on ziftomenib’s activity in the Japanese population, complementing evidence generated in the United States where the drug received FDA approval in late 2025 for adults with the same disease indication lacking satisfactory alternatives.

Safety and Efficacy Landscape

Data from the U.S. pivotal study demonstrated a composite CR rate of approximately 40 % in the target cohort, with manageable adverse events predominantly comprising hematologic cytopenias, nausea, and fatigue. Grade ≥ 3 adverse events were observed in 12 % of patients, and the drug exhibited a favorable safety profile relative to conventional chemotherapy. The current Japanese study will validate these findings within a distinct pharmacogenomic and healthcare context, ensuring that efficacy and tolerability are consistent across populations.

Regulatory Strategy and Global Development

Kyowa Kirin, in partnership with Kura Oncology, holds a global license agreement for menin inhibitors. Kyowa Kirin will lead development and commercial strategy outside the United States, while Kura will manage U.S. affairs. Upon completion of the Japanese Phase 2 trial, Kyowa Kirin intends to file a regulatory application with the Pharmaceuticals and Medical Devices Agency (PMDA) to facilitate market access in Japan.

The company’s chief medical officer emphasized a patient‑centred approach, noting that the approval of ziftomenib fills a critical gap for patients who have exhausted standard treatments. The regulatory pathway involves submission of the full clinical dossier, including safety data, efficacy outcomes, and pharmacoeconomic analyses, to support a reimbursement decision under Japan’s health‑care system.

Implications for Clinical Practice and Healthcare Systems

  • Clinical Practice: The availability of ziftomenib in Japan would expand therapeutic options for clinicians managing relapsed or refractory NPM1‑mutated AML. Given its oral route of administration, the drug offers logistical advantages over intravenous regimens, potentially improving patient adherence and quality of life.
  • Healthcare Systems: Integration of ziftomenib into treatment algorithms necessitates cost‑effectiveness analyses to guide reimbursement decisions. Early access to data on real‑world effectiveness and safety will inform payer and provider strategies.
  • Research and Development: The trial aligns with Kyowa Kirin’s broader initiative to accelerate the delivery of novel hematologic therapies. Success in Japan may serve as a platform for expanded indications, combination regimens, and cross‑border collaborations.

Conclusion

The initiation of the Japanese Phase 2 registration trial for ziftomenib underscores Kyowa Kirin’s commitment to advancing precision therapies for hematologic malignancies. By rigorously assessing composite remission rates and safety outcomes in a well‑characterized patient cohort, the study aims to provide robust evidence to support regulatory approval and clinical implementation, ultimately addressing a substantial unmet need in relapsed or refractory NPM1‑mutated AML.